Bimifree Combi, 0.3 mg/ml + 5 mg/ml, eye drops, solution
Bimatoprost + Timolol
Bimifree Combi contains two active substances (bimatoprost and timolol) that lower eye pressure. Bimatoprost belongs to a group of medicines called prostamides, prostaglandin analogs. Timolol belongs to a group of medicines called beta-blockers. The eye contains a clear, watery fluid that nourishes the inside of the eye. The fluid is constantly drained from the eye and replaced by new fluid. If the fluid cannot be drained quickly enough, the pressure in the eye increases, which can eventually lead to vision damage (causing a disease called glaucoma). The action of Bimifree Combi is to reduce the production of fluid and increase the amount of fluid drained. This leads to a decrease in pressure inside the eye. Bimifree Combi eye drops are used to treat high pressure in the eye in adults, including the elderly. High pressure can lead to glaucoma. The doctor will prescribe Bimifree Combi when the action of other eye drops containing beta-blockers or prostaglandin analogs is insufficient. The medicine does not contain preservatives.
Before starting treatment with Bimifree Combi, the patient should discuss with their doctor or pharmacist if they have or have had any of the following conditions:
Before anesthesia for surgery, the patient should tell their doctor about using Bimifree Combi, as timolol may affect the action of some anesthetics. During treatment with Bimifree Combi, the medicine may cause loss of fat tissue around the eye, which can lead to deepening of the eyelid fold, sunken eyes, drooping eyelids (ptosis), skin tension around the eye (dermatochalasis), and increased visibility of the lower white part of the eye (visibility of the lower part of the sclera). These changes are usually mild, but if they are pronounced, they can affect the field of vision. The changes may disappear after discontinuation of Bimifree Combi treatment. Bimifree Combi may also cause darkening and excessive growth of eyelashes, as well as darkening of the skin around the eyelid. It may also darken the color of the iris. These changes may be permanent. The changes may be more noticeable when treating only one eye. If Bimifree Combi comes into contact with the skin, it may cause hair growth.
Bimifree Combi should not be used in children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are taking or have recently taken, as well as any medicines they plan to take. Bimifree Combi may affect the action of other medicines or other medicines taken by the patient may affect the action of Bimifree Combi, including eye drops used to treat glaucoma. The patient should tell their doctor about taking or planning to take medicines that lower blood pressure, heart disease medicines, diabetes medicines, quinidine (a medicine used to treat heart disease or certain types of malaria), or depression (fluoxetine, paroxetine). If the patient is using other eye drops at the same time,they should leave at least a 5-minute interval between administrations of the next medicines. Eye ointments should be used last.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine. Bimifree Combi should not be used during pregnancy, unless the doctor recommends otherwise. Bimifree Combi should not be used during breastfeeding. Timolol may pass into breast milk. Before taking any medicine during breastfeeding, the patient should consult their doctor.
Bimifree Combi may cause loss of sharp vision in some patients. The patient should not drive or operate machines until the symptoms have resolved.
The medicine contains 1.4 mg of phosphates per milliliter. In patients with severe damage to the clear, front part of the eye (cornea), phosphates may rarely cause corneal clouding due to calcium deposition during treatment.
This medicine should always be used exactly as prescribed by the doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist. The recommended dose is one drop into each eye that needs treatment once a day, in the morning or evening. The medicine should be used every day at the same time. Bimifree Combi has not been studied in patients wearing contact lenses. Before using the medicine, the patient should remove their contact lenses and wait at least 15 minutes before putting them back on. Bimifree Combi is a sterile solution that does not contain preservatives. See section 6. What Bimifree Combi looks like and what the packaging contains.
If the drop does not get into the eye, the patient should repeat the attempt to administer the drop.
Figure 1.
Figure 2.
Figure 3.
Figure 4.
In case of using more than the recommended dose of Bimifree Combi, it is unlikely to cause serious harm. The next dose should be taken at the usual time. In case of doubt, the patient should consult their doctor or pharmacist.
In case of missing a dose of Bimifree Combi, the patient should use a single drop as soon as they remember and then continue with their usual dosing schedule. The patient should not use a double dose to make up for the missed dose.
Bimifree Combi should be used every day to be effective. If the patient has any further doubts about using this medicine, they should consult their doctor or pharmacist.
Like all medicines, Bimifree Combi can cause side effects, although not everybody gets them. In general, the patient can continue using the eye drops if the side effects are not severe. If the patient has any doubts, they should consult their doctor or pharmacist. The patient should not stop using Bimifree Combi without discussing it with their doctor. During treatment with Bimifree Combi, the following side effects may occur:
May occur in at least 1 in 10 patients
Related to the eye
redness.
Related to the area around the eye:
loss of fat tissue around the eye, which can lead to deepening of the eyelid fold, sunken eyes, drooping eyelids (ptosis), skin tension around the eye (dermatochalasis), and increased visibility of the lower white part of the eye (visibility of the lower part of the sclera).
May occur in 1 to 9 in 100 patients
Related to the eye
burning sensation, itching, stinging, irritation of the conjunctiva (the transparent membrane covering the eye), sensitivity to light, eye pain, stickiness of the eye, dryness of the eye, feeling of a foreign body in the eye, minor damage to the surface of the eye (with or without inflammation), blurred vision, redness and itching of the eyelids, hair growth around the eye, darkening of the eyelids, darker skin tone around the eye, lengthening of eyelashes, eye irritation, excessive tearing, swelling of the eyelids, limited vision.
Related to other parts of the body
runny nose, dizziness, headache.
May occur in 1 to 9 in 1000 patients
Related to the eye
abnormal sensations in the eye, inflammation of the iris, swelling of the conjunctiva (the transparent membrane covering the eye), eyelid pain, eye fatigue, ingrown eyelashes, darkening of the iris, separation of the eyelid from the eye surface, darkening of the eyelashes.
Related to other parts of the body
shortness of breath.
Related to the eye
cystoid macular edema (swelling of the retina in the eye leading to vision impairment), eye swelling, blurred vision.
Related to other parts of the body
breathing difficulties/wheezing, symptoms of allergic reactions (swelling, redness of the eye and skin rash), taste disturbances, slow heart rate, sleep disturbances, nightmares, asthma, hair loss, fatigue.
Additional side effects have been observed in patients using eye drops containing timolol or bimatoprost, so they may also occur during treatment with Bimifree Combi. Like other ophthalmic medicines used locally, timolol may penetrate the systemic circulation. This may lead to similar side effects as when beta-adrenergic blockers are taken orally and/or intravenously. The frequency of systemic side effects after using eye drops is lower than after oral or intravenous administration. These side effects include those observed with the use of bimatoprost and timolol in the treatment of eye diseases:
Other side effects reported in relation to the use of eye drops containing phosphates In very rare cases, in some patients with significant damage to the outer, transparent layer of the eyeball (cornea), during treatment, dull spots appeared on the cornea due to calcium deposition.
If the patient experiences any side effects, including those not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products Al. Jerozolimskie 181C 02-222 Warsaw Tel.: +48 22 49 21 301 Fax: +48 22 49 21 309 Website: https://smz.ezdrowie.gov.pl Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
There are no special precautions for storage. The medicine should be kept out of sight and reach of children. Do not use this medicine after the expiry date stated on the carton and bottle. The expiry date refers to the last day of the month. The notation on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot means the batch number. After opening the bottle - store for 90 days at a temperature below 25°C. The bottle should be discarded after 90 days from its first opening. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
Bimifree Combi is a clear, colorless solution. The medicine is available in white bottles with a capacity of 5 ml (LDPE) containing 3 ml of solution, with a multi-dose dropper (HDPE) that prevents contamination of the solution with bacteria thanks to a system consisting of a silicone membrane and air filtration entering the bottle, with a cap made of HDPE with a tamper-evident ring, in a cardboard box. Packaging: 1 bottle with a capacity of 5 ml containing 3 ml of solution. 3 bottles with a capacity of 5 ml containing 3 ml of solution each. Not all pack sizes may be marketed.
Polpharma S.A. ul. Pelplińska 19, 83-200 Starogard Gdański tel. +48 22 364 61 01
Rafarm S.A. Thesi Pousi Xatzi Agiou Louka Paiania, 190 02 Greece
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.